Pfizer leads busy bond week; GSK gets green light for U.K. expansion;


@FiercePharma: Roche unveils more plans for plant expansions in Switzerland. Story | Follow @FiercePharma

@TracyStaton: If AstraZeneca were Harry Potter, would that make Pfizer Voldemort? More | Follow @TracyStaton

@EricPFierce: China forewarns drugmakers. It's not messing around when it comes to bribery as a sales tool. More | Follow @EricPFierce

@CarlyHFierce: First, bribery. Now, China floats tax-evasion accusations against GlaxoSmithKline. News | Follow @CarlyHFierce

> Pfizer ($PFE) is leading a busy week of bond sales, issuing $4.5 billion. Report

> GlaxoSmithKline ($GSK) has won approval for its £100 million ($168 million) plans to expand a pharmaceutical plant in Worthing, U.K. More

> Endo ($ENDP) has acquired from Zogenix ($ZGNX) the rights to its Sumavel DosePro, a needle-free delivery system for migraine treatment. Release

> Forest Labs ($FRX) is selling its building in Commack, NY. Story

> Reckitt Benckiser, looking for deal approval, has applied to New Zealand's Commerce Commission seeking clearance to acquire Johnson & Johnson's ($JNJ) K-Y brand and product assets. More

> Indonesian herbal medicine maker Sido Muncul is buying pharmaceutical firm PT Berlico Mulia Farma for about 150 billion rupiah ($13.1 million). More

Medical Device News

@FierceMedDev: Water Street plans to grow a German specialty Dx company into a major player, through investment and M&A. ICYMI from FierceDiagnostics | Follow @FierceMedDev

@VarunSaxena2: It's official: Alere is spinning off its diagnostics biz. More | Follow @VarunSaxena2

@MichaelGFierce: From Harvard Research: Herpes-loaded stem cells used to kill brain tumors. More | Follow @MichaelGFierce

@EmilyWFierce: Gelesis brought in $12M for superabsorbent hydrogel technology that swells in the stomach to treat obesity. More from MedCityNews | Follow @EmilyWFierce

> Acufocus gears up for FDA scrutiny on corneal implant. Item

> It's official: Alere is spinning off its diagnostics biz. Article

> CMS closer to coverage for Abbott's MitraClip. More

Biotech News

@FierceBiotech: Why did Pfizer's big fiesta for palbociclib fizzle? Story | Follow @FierceBiotech

@JohnCFierce: Elotuzumab: Bristol-Myers nabs another 'breakthrough' cancer drug title. More | Follow @JohnCFierce

@DamianFierce: From yesterday: The redacted bit of Pfizer's letter sort of spells out their passive-aggressive strategy. Image | Follow @DamianFierce

@EmilyMFierce: Scientists can have an impact on the antibiotic crisis by engaging the public and talking to media, says Ian Lipkin. | Follow @EmilyMFierce

> AstraZeneca slaps down Pfizer's 'final' $119B takeover bid. More

> Boehringer, InterMune wow IPF field with a slate of groundbreaking trial data. Story

> Another animal health biotech plots an IPO. Item

CRO News

> WuXi wraps up construction on a new biologics shop. Item

> Bayer agrees to share trial data, but not without a list of caveats. Article

> PRA amps up its biologics footprint amid industry shift. Story

> Evotec's hybrid CRO approach pays off in Q1. More

> WuXi scores more double-digit growth amid its global expansion. Report

Biotech IT News

> Venter nabs AstraZeneca's R&D IT chief for Human Longevity. News

> Bayer, Boehringer extend access to clinical trial data. Item

> NIH lays out up to $20B in IT spending over coming decade. More

> HCL Tech adds Novartis to roster of Big Pharma clients. Story

> GSK signs up to access Metabolon's bioinformatics tools. Article

And Finally... Which is better at detecting cancer, a laboratory or a Labrador retriever? It could be the latter. Story